Close Menu

NMTRC

The Neuroblastoma and Medulloblastoma Translational Research Consortium will conduct a 14-patient trial in which it will try to pinpoint treatments that best suit individual participants based on their gene expression profiles.

The trial, which has been approved by the Food and Drug Administration and will begin enrollment immediately, will use next-generation sequencing and gene expression analysis to provide information about a patient's disease state and to identify targets for therapy.

Kaiser Health News reports San Francisco and Alameda counties in California are no longer using Verily Life Sciences' COVID-19 testing program.

The New York Times reports that developers in New York City are increasingly interested in life science spaces.

A UK study has found that antibodies against SARS-CoV-2 may decline over time, Reuters reports.

In PNAS this week: genetic and epigenetic variation in individuals with diabetic kidney disease, spontaneous genetic alterations in Saccharomyces cerevisiae, and more.